EI
STOK icon

EAM Investors’s Stoke Therapeutics STOK Stock Holding History

EAM Investors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.69M Sell
52,000
-65,823
-56% -$2.16M 0.2% 176
2025
Q4 		$3.74M Sell
117,823
-2,358
-2% -$70.9K 0.42% 127
2025
Q3 		$2.78M Buy
+120,181
New +$2.06M 0.32% 145
2024
Q4 		– Sell
-30,781
Closed -$378K – 349
2024
Q3 		$378K Sell
30,781
-6,856
-18% -$97.1K 0.06% 237
2024
Q2 		$508K Sell
37,637
-8,208
-18% -$111K 0.08% 229
2024
Q1 		$619K Buy
+45,845
New +$278K 0.1% 226

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EAM Investors's STOK Position: Q1 2026 in Review

EAM Investors reduced its Stoke Therapeutics (STOK) stake by 56% in Q1 2026, selling an estimated $2.16M and leaving 52,000 shares worth $1.69M. The position accounts for 0.2% of the portfolio, ranked #176.

EAM Investors first reported a position in STOK in Q1 2024 and has held it in 6 quarters since. The position peaked at $3.74M in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • EAM Investors held 52,000 shares of Stoke Therapeutics worth $1.69M as of Q1 2026.
  • EAM Investors sold 65,823 Stoke Therapeutics shares in Q1 2026, an estimated $2.16M.
  • Stoke Therapeutics made up 0.2% of EAM Investors's portfolio in Q1 2026, its #176 holding.
  • EAM Investors first reported a position in Stoke Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • EAM Investors's Stoke Therapeutics position peaked at $3.74M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.